Endocrine Care in Duchenne Muscular Dystrophy

Endocrine care is one of the least discussed and most consequential parts of Duchenne muscular dystrophy management. Long-term corticosteroids, the cornerstone of medical care for many patients, push the endocrine system in ways that show up over months and years rather than weeks. Recognizing the problems early and managing them proactively is part of standard care, even when it is not part of routine clinic conversations.

This post is a practical overview. The actual plan belongs to the care team, ideally including a pediatric or adult endocrinologist familiar with neuromuscular disease.

Why endocrine care matters in DMD

Two forces drive the endocrine picture in DMD. Long-term glucocorticoid therapy, often started in childhood and continued for years, suppresses the body’s own cortisol production, reduces growth velocity, can delay puberty, contributes to weight gain, and affects bone and glucose metabolism. Progressive muscle weakness adds reduced activity, altered body composition, and changes in nutritional intake.

The result is a predictable cluster of endocrine concerns: short stature, delayed or absent puberty, adrenal suppression, obesity, low bone density, and sometimes glucose intolerance.

The 2018 international care considerations include endocrine surveillance as part of standard DMD management. (Birnkrant et al., Lancet Neurology 2018, Part 3)

A care gap

Despite the importance of endocrine surveillance, real-world adherence to these recommendations is mixed. A recent national survey of families found that while the great majority of patients were on corticosteroids, only about half were followed regularly by endocrinology, and a meaningful minority had never been seen by one. (Endocrine surveillance in DMD, national survey, PMC)

That gap matters. Endocrine complications are often silent until they cause a problem, which makes proactive surveillance the difference between catching and missing them.

Growth

Children with DMD on long-term glucocorticoids commonly grow more slowly than peers. Growth assessment is part of routine DMD care, with heights tracked every six months. (PPMD, Growth and Puberty)

Endocrinology referral is typically considered when growth velocity drops below age-appropriate norms, when height drops to the third percentile, or when growth slows below roughly 4 cm per year. The endocrinologist evaluates causes that go beyond steroid effect, including thyroid, growth hormone, and nutritional contributors.

Growth hormone therapy is considered in selected cases. It is not a routine intervention; it requires evaluation and weighing of risks and benefits with the team.

Puberty

Delayed or absent puberty is common in DMD. Pubertal status is typically assessed every six months starting around age 9, and an endocrinology referral is considered if no signs of puberty appear by approximately age 14.

Hormone replacement therapy can be appropriate for selected patients to support the physical and psychological development that puberty usually brings. The decision is individualized.

Adrenal suppression

Long-term corticosteroid use suppresses the body’s own cortisol production. In a healthy person, the adrenal glands surge cortisol output during illness, injury, or surgery; in a patient with adrenal suppression, that surge does not happen. Without supplemental steroid dosing, the result can be adrenal crisis: severe weakness, vomiting, low blood pressure, and collapse.

This is the precaution behind stress-dose steroid protocols. Every DMD patient on long-term corticosteroids should have a clear plan for what to do during illness, what to do during surgery or significant injury, and how to recognize the signs of adrenal crisis.

For background, see emergency preparedness for DMD families and corticosteroids in DMD.

Weight, body composition, and metabolic health

Corticosteroids increase appetite and promote fat accumulation. Combined with reduced physical activity, weight gain is one of the most visible side effects of treatment, and one of the most discussed by families.

Endocrine and nutritional teams work together on this. Modest, sustainable changes in diet and activity, rather than aggressive restriction, are the foundation. Routine monitoring of blood pressure, glucose, and lipid profiles catches the metabolic consequences of excess weight when they begin.

For background, see nutrition in DMD.

Bone health

Bone density is a major endocrine concern in DMD. Vitamin D, calcium, fracture history, DEXA results, and corticosteroid dosing all factor into bone-health planning, which is usually coordinated between endocrinology and the neuromuscular team.

For more, see bone health in DMD.

Building endocrinology into the care plan

A practical approach for families:

• Ask the neuromuscular team for a referral to a pediatric or adult endocrinologist familiar with DMD.
• Establish a baseline visit at the time corticosteroids are started or soon after.
• Schedule follow-up at intervals matched to the patient’s age and clinical status, typically every six to twelve months.
• Maintain a written stress-dose steroid plan, accessible to the family and any care team that may see the patient in an emergency.
• Track growth, weight, blood pressure, glucose, and bone health over time.

This is unglamorous medicine. It quietly prevents most of the bad outcomes it monitors for.

What is still uncertain

Optimal endocrine surveillance intervals, the role of newer steroid-modifying therapies in changing the endocrine picture, and best practices for transitioning patients from pediatric to adult endocrinology all continue to be studied.

The reasonable framing is that endocrine care in DMD is part of standard care, not an optional add-on. The decisions belong to the patient, family, and care team.

For related reading, see corticosteroids in DMD, bone health in DMD, and DMD standards of care.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.